Kopran Ltd.
Snapshot View

242.05 -12.70 ▼-5.0%

04 August 2021, 04:00:00 P.M.
Volume: 20,959

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.kopran.com
Financial Indicators
Market Cap 1,046.93 Cr.
Earnings per share (EPS) 14.24 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 16.99 Trailing Twelve Months Ending 2021-03
Industry PE 32.74 Trailing Twelve Months Ending 2021-03
Book Value / Share 56.65 Trailing Twelve Months Ending 2021-03
Price to Book Value 4.27 Calculated using Price: 242.05
Dividend Yield 0.62 Period Ending 2020-03
No. of Shares Subscribed 4.33 Cr. 43,252,602 Shares
FaceValue 10
Company Profile

The company was incorporated on April 26, 1958 as a private limited company under the name Kopran Chemical Company Pvt. Ltd. by Ramanlal V Shah Sevantilal, A Shah , Chimanlal G Sheth and Jivanalal M Shah. In 1972, the company’s management was acquired by Chemo Pharma Laboratories Ltd and the Company’s products were marketed by them.

Promoted by the Parijat Enterprises, Kopran is currently an integrated health care company. Kopran has used research-based technology to contribute towards total health-care. The company started modestly as a Semi Synthetic Penicillin (SSP) player and expanded to becomes the largest SSP Player in India with an annual SSP facility of over 1200 tones per annum.Subsequently the SSP business was hived off into a separate Company in a joint venture with Synpac Pharmaceuticals Ltd, UK.Kopran Laboratories Ltd. markets and supports high-tech life-saving medical equipments and diagnostics reagents since 1988.

Kopran Research Laboratories Ltd. (KRLL) is an emerging research organisation with particular interests in the areas of drug discovery, polymer technology and synthesis of new molecules.

Kopran is working towards creating and maintaining a global presence.Presence in Africa through Kampala Pharmaceutical Industries (KPI),a pharmaceutical company engaged in the manufacture and marketing of finished dosage forms in Uganda.

The company is having presence in the Middle East Market through a joint venture with Dubai Investment Corporation a leading investment company in Dubai for the manufacture and marketing of finished dosage forms in Dubai.

KRLL is a 100% subsidiary of Kopran Ltd.  KRLL is recognised by the Department of Science and Industrial Research (DSIR), Government of India. The company is staffed with competent and dedicated team of scientists.

Product range of the company includes:

Finished Dosage Forms

  • Antibiotics/antibacterials
  • Anti-malarial
  • Cadiovasculars
  • Pain management
  • Anthelminthics
  • Antiprotozoals
  • Antidiabetics
  • Gastrointestinals
  • Drug for erectile dysfuntion
  • Antiallergics
  • Respiratory/anti-asthmatics
  • Metered dose inhalers
  • Dry powder inhalers
  • Antiviral

Active Pharmaceutical Ingredients

  • Anti-hypertensives
  • Macrolides
  • Taste Masked
  • Cephalosporins 
  • Under Development
  • Others

Achievements/ recognition:

  • Kopran has a state of art manufacturing plants (Penicillin & General) approved by: -MCC (South Africa) -TGA, Australia and FDA, USA are in the pipeline

Future plans:

  • Brand Equity Development
  • Research for New Chemical Entities
  • Globalise its operations thus making Kopran a truly International Pharmaceutical Company.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-4.99%
1 Week
-0.74%
1 Month
+1.72%
3 Month
+35.07%
6 Month
+93.10%
1 Year
+360.61%
2 Year
+704.15%
5 Year
+375.54%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 7.15 13.39 17.65 -43.06 12.19 17.71 15.21 15.34 11.74
Return on Capital Employed (%) 7.92 11.81 14.27 -12.48 13.09 19.24 13.88 16.30 13.69
Return on Assets (%) 2.19 4.33 6.11 -13.63 3.98 7.15 6.77 7.27 5.84

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 86 97 115 99 109 125 145 168 190
Non Curr. Liab. 68 73 67 18 33 32 31 46 40
Curr. Liab. 96 93 117 158 122 136 136 135 140
Minority Int.
Equity & Liab. 250 263 299 275 264 293 312 349 370
Non Curr. Assets 144 141 139 105 110 114 118 142 148
Curr. Assets 107 123 160 170 154 180 194 208 223
Misc. Exp. not W/O
Total Assets 250 263 299 275 264 293 312 349 370

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 199 250 303 326 296 310 313 358 360
Other Income 6 2 2 7 2 11 11 4 1
Total Income 205 252 305 332 299 320 324 362 360
Total Expenditure -178 -217 -260 -294 -266 -274 -284 -312 -313
PBIDT 27 35 45 38 33 47 40 49 47
Interest -10 -12 -14 -13 -13 -14 -9 -9 -9
Depreciation -12 -12 -13 -10 -8 -8 -9 -9 -10
Taxation -5 -2 -8 -7
Exceptional Items -54 -1 -1
PAT 5 11 17 -39 11 20 20 24 21

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 35 15 3 46 29 16 26 25 31
Cash Fr. Inv. -10 -9 -9 -10 -9 -18 -11 -25 -13
Cash Fr. Finan. -19 -12 7 -37 -19 2 -15 -1 -18
Net Change 6 -7 0 0 0 0 0 0 0
Cash & Cash Eqvt 7 1 1 1 1 1 0 0 1

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 43.78 43.78 43.78 43.78 43.78 43.78 43.78 43.78 43.78
Public 56.22 56.22 56.22 56.22 56.22 56.22 56.22 56.22 56.22
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 02 Aug 2021
Reg. 34 (1) Annual Report
Pursuant to Regulation 34(1) of the Listing Regulations we are submitting the Annual Report of the Company for Financial Year 2020-21 to the exchange. The 62nd Annual General Meeting of the Company will be held on Tuesday 31st August 2021 at 12.30 p.m. (IST) via videoconferencing (VC)/other audio visual means (OAVM). The e-mail communication of the Notice to the 62nd AGM shall be dispatched through NSDL from 3rd August 2021 onwards.
Wed, 28 Jul 2021
Subsidiary Company Updates
Production at factory of Kopran Research Laboratories Limited Subsidiary Company has resumed operations from midnight 27th July 2021 which was stopped from 22nd July 2021 due to non availability of electricity supply water supply and manpower availability on account of floods situation in Mahad Raigad district.
Wed, 28 Jul 2021
Subsidiary Company Updates
Production at factory of Kopran Research Laboratories Limited Subsidiary Company has resumed operations from midnight 27th July 2021 which was stopped from 22nd July 2021 due to non availability of electricity supply water supply and manpower availability on account of floods situation in Mahad Raigad district.

Technical Scans View Details

Tue, 03 Aug 2021
Close Crossing Last Week High Close Crossing Last Week High
Closing Above Previous High Closing Above Previous High
Close Within 52 Week High Zone Close Within 52 Week High Zone
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index
S Close Above Last Week High

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,527.75 785.75 -1.1%
Divi's Laboratories Ltd. 131,785.24 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. 79,333.82 4,768.80 +1.0%
Cipla Ltd. 75,796.16 939.65 +1.2%
Cadila Healthcare Ltd. 60,170.47 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. 58,468.59 4,066.40 -0.6%
Piramal Enterprises Ltd. 57,915.28 2,550.50 +1.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.40 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2021-03 66.41 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.66 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 31.52 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 28.20 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 388.86 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 43.47 2,550.50 +1.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2021-03 14.18 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.44 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 4.15 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 4.63 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.72 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1.69 2,550.50 +1.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 0.10 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,550.50 +1.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 14.13 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,550.50 +1.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 17.85 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,550.50 +1.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 6,969.40 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 19,159.59 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,550.50 +1.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,984.29 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 2,401.30 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,550.50 +1.7%